National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.
Cancer Society's Retiring Chief Shares Parting Thoughts
Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.
#LungCancer #NonSmallCellLungCancer #CancerResearch With the new cobas Epidermal Growth Factor Receptor test, doctors at some public hospitals are now able to detect the presence of gene mutations. About half of non-small cell lung cancer is linked to a genetic epidermal growth factor receptor (EGFR) mutation - affecting mostly female non-smokers.
Gefticip is made by using gefitinib and it basically belongs to a class of anti-cancer medications known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It is used for curing non-small cell lung cancer. The medicine functions by blocking the action of a certain naturally occurring substance that facilitates the growth of cancer cells.
EGFR stains using the DakoCtomation kit on colon carcinomas. Nonspecific cytoplasmic staining (left) is common, and should be ignored. - http://www.propath.com/companies/press-clippings/26-newsletters/267-epidermal-growth-factor-receptor-and-erbitux-march-2004
Epidermal Growth Factor Receptor and Its Applications - The discovery of growth factors won the Nobel Prize in Medicine in 1986, implying their importance. Epidermal growth factor receptor, EGFR, one of such factors, exists on cell surface and is activated by binding of its specific ligands. EGFR is a member of the receptor tyrosine kinase family whose members play a critical role in oncogenesis. Mutations affecting EGFR expression or activity could result in cancers, ...